One of the first randomized controlled trials of its kind has concluded that low-level light therapy is safe in the treatment of moderate traumatic brain injury (TBI).
The investigation of 68 patients with moderate TBI showed that light therapy statistically significantly altered multiple diffusion tensor parameters in the late subacute stage. The trial provides evidence that light therapy engages the neural substrates that affect the pathophysiologic factors associated with moderate traumatic brain injury.
"The primary objective of the study was to show that light is safe," senior author Rajiv Gupta, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, told Medscape Medical News. "And to the extent that we can tell, we did not observe any adverse reactions in the light-treated group vs the sham group.
"What is currently known about this relationship comes primarily from animal models and basic biology research," Gupta continued. "Our study is the first one to establish its effect in humans."
The study was published online September 14 in JAMA Network Open.
Low-level light therapy incorporates near-infrared light and is thought to elicit biostimulation through mitochondrial light absorption. Preclinical research has examined the effects of low-level light therapy, including its vascular and neuroprotective functions, on various subsystems.
Animal studies have shown that functional recovery from TBI is improved with low-level light therapy. In one such investigation, mice that were treated with low-level light therapy for 4 hours after TBI had a better functional outcome than mice that were exposed to a sham treatment.
"It has been known for a number of years that cells have activity to light, because certain wavelengths of light interfere with and modulate mitochondrial metabolism, such as upregulating ATP [adenosine triphosphate] production and blood flow," said Gupta.
"Some animal models have shown that those effects translate into full response, but it had never been shown in humans. Ours is the first study in moderate traumatic brain injury that the brain perceives light and in a measurable way," he added.
The single-center, prospective, double-blind, placebo-controlled, parallel-group trial was conducted between November 2015 and July 2019. Sixty-eight patients with moderate TBI were randomly assigned to receive either low-level light or sham therapy.
Transcranial low-level light therapy was administered using a custom-built helmet equipped with 18 clusters of 20 near-infrared light-emitting diodes; therapy was initiated within 72 hours of injury. The treatment was divided into three 20-minute sessions with at least 12 hours between each one. Sham treatment was delivered using the same helmet.
MRI was performed in three stages of recovery the acute phase (within 72 hours of injury), the early subacute phase (2 3 weeks of injury), and the late subacute phase (approximately 3 months after injury).
Brain imaging software assessed neuroreactivity to light therapy and the overall health of the brain's white matter. Neurocognitive assessments using the Rivermead Post-Concussion Questionnaire were performed at the same time as MRI and at 6 months post injury.
Of the 68 patients who originally underwent randomization, 43 (mean age, 50.5 17.4 years; 21 women) were included in the final analysis. All had undergone at least one MRI scan. Forty patients underwent at least two MRI scans, 18 in the low-level light therapy group and 22 in the sham therapy group.
The investigators found that all 18 patients who successfully completed low-level light therapy did so without any complications. Interestingly, the helmet proved feasible for all patients, even those with subgaleal hemorrhage or soft tissue swelling and those for whom small dressings had been applied to portions of the head.
The study showed a reduction in all symptom scores for patients who received low-level light therapy. However, these changes were not statistically significantly different from those in the sham therapy group. This finding, Gupta said, suggests that low-level light therapy is safe in the acute stage of TBI.
Measures of neuroreactivity also differed between the two groups. Although the passage of time had a statistically significant effect on most diffusion parameters in both groups, the parameters differed by treatment status.
Radial diffusivity, mean diffusivity, and fractional anisotropy all showed significant time and treatment interactions at the 3-month time point in patients treated with low-level light therapy.
"Most people don't realize that in the near-infrared spectrum, the skull is very transparent to light. So about 3% of the light that we are applying transcranially will reach the surface of the brain, and a good number of those photons go fairly deep into the brain," said Gupta.
The study was not without limitations, which included its lack of power to assess the efficacy of low-level light therapy on the symptom burden of moderate TBI. The researchers also acknowledge that the trial did not include 6- or 12-month follow-up MRI scans.
Although Gupta was quick to acknowledge the preliminary nature of the investigation, he and his colleagues are confident that it shows the feasibility and safety of low-level light therapy in this patient population.
What's more, the results provide what the researchers note is the first direct evidence that transcranial low-level light therapy targets and engages the neural substrates that may play a role in the pathophysiologic effects of moderate TBI.
Given these potential benefits, the investigators believe low-level light therapy has the potential to have a marked clinical effect for these patients.
"There are very few interventions that are known to be effective and useful after traumatic brain injury, and here now we have an intervention that is easy to administer, portable, and as we have shown, is safe," he said.
"While we have yet to demonstrate any effectiveness with low-level light therapy, if we do establish such efficacy, then it becomes a technology that is very easily applied, very available, and very inexpensive. You can have it anywhere there's a risk of injury," he added.
In an accompanying commentary, Juliana Belo Diniz, MD, PhD, of the Faculdade de Medicina da Universidade de So Paulo, So Paulo, Brazil, noted that short of preventing TBI from occurring in the first place, secondary and tertiary prevention efforts may help stem the development of disability after head trauma.
"If proven safe and effective, low-level light therapy could reduce disabilities produced by traumatic brain injury and improve outcomes from such rehabilitation programs," writes Diniz, who was not involved in the study.
That said, Diniz recognized that it is unlikely that the novel therapeutic approach will assume an isolated role in the secondary prevention of physical, cognitive, and emotional repercussions of TBI.
"Individually tailored multidisciplinary rehabilitation programs will probably continue to be the standard of care after moderate and severe traumatic brain injury. The adjuvant use of low-level light therapy will be justifiable if proven cost-effective in reducing trauma sequelae or in shortening time to recovery from trauma," she adds.
The study was supported the US Air Force, the Joint Warfighter Medical Research Program, and the Congressionally Directed Medical Research Program. Gupta and Diniz have disclosed no relevant financial relationships.
JAMA Netw Open. Published online September 14, 2020. Full text, Commentary
For more Medscape Neurology news, join us on Facebook and Twitter.
Originally posted here:
Low-Level Light Therapy Safe for TBI in Humans - Medscape
- Vascular Cell and Molecular Biology | Center for Vascular Biology | Weill Cornell ... - April 13th, 2018 [April 13th, 2018]
- APVBO-Asia Pacific Vascular Biology Organization Conference - April 18th, 2018 [April 18th, 2018]
- Vascular Biology Conferences | Vascular Surgery ... - May 5th, 2018 [May 5th, 2018]
- Vascular Discovery: From Genes to Medicine - May 7th, 2018 [May 7th, 2018]
- 2019 Vascular Cell Biology Conference GRC - May 26th, 2018 [May 26th, 2018]
- Biology 211: Taxonomy of Flowering Plants - June 7th, 2018 [June 7th, 2018]
- esm-evbo2019.org - Menu - July 27th, 2018 [July 27th, 2018]
- Vascular Biology | Pulmonary, Allergy, Sleep & Critical ... - November 16th, 2018 [November 16th, 2018]
- Lower vascular plant | biology | Britannica.com - November 18th, 2018 [November 18th, 2018]
- Vascular Biology - NAVBO - November 20th, 2018 [November 20th, 2018]
- 2019 Cerebral Vascular Biology Conference - cvent.com - November 21st, 2018 [November 21st, 2018]
- PPARs and Their Emerging Role in Vascular Biology ... - November 26th, 2018 [November 26th, 2018]
- Vascular Biology Chicago Medicine - November 30th, 2018 [November 30th, 2018]
- Vascular Biology | Society for Vascular Surgery - November 30th, 2018 [November 30th, 2018]
- Vascular Biology 2018 - NAVBO - December 19th, 2018 [December 19th, 2018]
- Vascular Biology 2019 - NAVBO - December 20th, 2018 [December 20th, 2018]
- Vascular Biology - January 22nd, 2019 [January 22nd, 2019]
- pvb2019.org Plant Vascular Biology Conference 2019 - January 31st, 2019 [January 31st, 2019]
- Plant Physiology | Basic Biology - March 12th, 2019 [March 12th, 2019]
- Awards - esm-evbo2019.org - April 23rd, 2019 [April 23rd, 2019]
- Medication and Exercise to Prevent Muscle Loss - Next Avenue - September 24th, 2019 [September 24th, 2019]
- A Snail as Fast as a Bullet, and Other Darwin-Defying Marvels - Discovery Institute - September 24th, 2019 [September 24th, 2019]
- Nature up close: Life in the Humboldt Penguin National Reserve - CBS News - September 24th, 2019 [September 24th, 2019]
- Oklahoma new hires and promotions announced - Oklahoman.com - September 24th, 2019 [September 24th, 2019]
- Quinn Capers IV, MD - TCTMD - September 24th, 2019 [September 24th, 2019]
- Cardiovascular Repair And Reconstruction Devices Market Global Industry Insights by Top Vendors, Growth, Revenue and Forecast Outlook 2019-2025 -... - September 26th, 2019 [September 26th, 2019]
- Four health projects at Boston Childrens Hospital that could help adults - The Boston Globe - September 30th, 2019 [September 30th, 2019]
- Research Officer/ Postdoctoral Researcher - The Conversation AU - October 16th, 2019 [October 16th, 2019]
- UNSW skin cancer researcher Levon Khachigian hit with string of retractions - ABC News - October 16th, 2019 [October 16th, 2019]
- Michal Wszola: We Expect to Transplant the Bioprinted Bionic Pancreas in Three to Five Years - 3DPrint.com - October 24th, 2019 [October 24th, 2019]
- 'The Blob': This mysterious 'smart' slime can solve puzzles and make decisions - CNBC - October 24th, 2019 [October 24th, 2019]
- University of Maryland and DOD collaborate to study Tick-borne Infections using 3-D models of human blood vessels - Outbreak News Today - November 19th, 2019 [November 19th, 2019]
- Submerged Vegetation Mirrors Coast's Health - Coastal Review Online - November 19th, 2019 [November 19th, 2019]
- Another health warning for e-cigarette users that has nothing to do with lung disease - MarketWatch - November 19th, 2019 [November 19th, 2019]
- E-Cigarettes Take a Dangerous Toll on Heart Health - DocWire News - November 19th, 2019 [November 19th, 2019]
- Vascular biology Department of Surgery College of ... - November 19th, 2019 [November 19th, 2019]
- US Nobel laureates tell us what they think about cancer research, moonshots, the dark side, funding, meritocracy, herd mentality, Trump, and joy - The... - November 21st, 2019 [November 21st, 2019]
- Growing Organs in the Lab: One Step Closer to Reality - BioSpace - November 21st, 2019 [November 21st, 2019]
- Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock - Business Wire - November 21st, 2019 [November 21st, 2019]
- Another Study Suggests E-cigarettes Hurt Heart Health More Than Regular Cigarettes - Science Times - November 21st, 2019 [November 21st, 2019]
- Cleveland Clinic awarded $12 million by NIH to study the link between gut microbes and heart disease - Crain's Cleveland Business - November 21st, 2019 [November 21st, 2019]
- JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD) - Yahoo Finance - November 27th, 2019 [November 27th, 2019]
- Germ-free lungs of newborn mice are partially protected against hyperoxia - The Mix - November 27th, 2019 [November 27th, 2019]
- Bethesda Health Physician Group Welcomes Fellowship-Trained Endocrine Surgeon Jessica L. Buicko, MD, to Its Team - The Boca Raton Tribune - November 27th, 2019 [November 27th, 2019]
- 9 Harvard researchers named AAAS Fellows Harvard - Harvard Gazette - November 27th, 2019 [November 27th, 2019]
- Top Technical Advances of 2019 - The Scientist - December 29th, 2019 [December 29th, 2019]
- Growing up Tyrannosaurus rex: Osteohistology refutes the pygmy Nanotyrannus and supports ontogenetic niche partitioning in juvenile Tyrannosaurus -... - January 2nd, 2020 [January 2nd, 2020]
- UCC currently taking applicants for 21 jobs with some incredible pay - Cork Beo - January 2nd, 2020 [January 2nd, 2020]
- Vascular Biology | Surgery Research | Michigan Medicine ... - January 2nd, 2020 [January 2nd, 2020]
- Sandy Bottom wetlands to receive protection for 'national ecological significance' - Citizen Times - January 14th, 2020 [January 14th, 2020]
- Why biotech is a boon for patients and investors - Spear's WMS - January 14th, 2020 [January 14th, 2020]
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related... - January 14th, 2020 [January 14th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 Dagoretti News - Dagoretti News - January 18th, 2020 [January 18th, 2020]
- Scientists revealed the oldest known scorpion on Earth - Tech Explorist - January 18th, 2020 [January 18th, 2020]
- How biology creates networks that are cheap, robust, and efficient - Penn: Office of University Communications - January 18th, 2020 [January 18th, 2020]
- Genome editing heralds new era of disease research, therapy - The Augusta Chronicle - January 18th, 2020 [January 18th, 2020]
- Research Fellow in Vascular Stem Cell Biology job with QUEENS UNIVERSITY BELFAST | 195527 - Times Higher Education (THE) - February 10th, 2020 [February 10th, 2020]
- More than skin deep: the latest innovation in 3D printing - Med-Tech Innovation - February 10th, 2020 [February 10th, 2020]
- Examining the link between menopause and heart disease risk - Medical News Bulletin - February 10th, 2020 [February 10th, 2020]
- Women Face an Increased Risk of Heart Disease With AgeRunning Can Help - runnersworld.com - February 12th, 2020 [February 12th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 - Galus Australis - February 15th, 2020 [February 15th, 2020]
- Valentine's Day Matters of the Heart, Biopharma-Style - BioSpace - February 15th, 2020 [February 15th, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Sharon - February 22nd, 2020 [February 22nd, 2020]
- UI at 150 & Beyond: 'The Quad was the best no matter what the weather' - Champaign/Urbana News-Gazette - February 22nd, 2020 [February 22nd, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Dedham - February 23rd, 2020 [February 23rd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Wareham - March 22nd, 2020 [March 22nd, 2020]
- 'Little Foot' skull reveals how this more than 3 million year old human ancestor lived - HeritageDaily - March 22nd, 2020 [March 22nd, 2020]
- It's Not Only About Neurons - The Good Men Project - March 22nd, 2020 [March 22nd, 2020]
- Who is Sir Patrick Vallance and what is his role in government during coronavirus outbreak? - The Scottish Sun - March 22nd, 2020 [March 22nd, 2020]
- University of Washington Pathology Professor Dies of COVID-19 - The Scientist - March 22nd, 2020 [March 22nd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Rochester - March 23rd, 2020 [March 23rd, 2020]
- Ancient human ancestor 'Little Foot' probably lived in trees, new research finds - WBAP News/Talk - March 23rd, 2020 [March 23rd, 2020]
- Study shows similarity in anti-VEGF injection intervals for wet AMD - Ophthalmology Times - March 25th, 2020 [March 25th, 2020]
- aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform - BioSpace - March 25th, 2020 [March 25th, 2020]
- Health researchers find solution to life-threatening side effect - Mirage News - March 25th, 2020 [March 25th, 2020]
- European Vascular Biology Organisation | Advancing human ... - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Program | Boston Children's Hospital - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Research Program | Johns Hopkins ... - March 25th, 2020 [March 25th, 2020]
- Anatomy of a heatwave: how Antarctica recorded a 20.75C day last month - The Conversation AU - April 1st, 2020 [April 1st, 2020]
- Who is Sir Patrick Vallance and is he speaking at todays government coronavirus press briefing? - The Sun - April 1st, 2020 [April 1st, 2020]